Molly R Petersen1, Eshan U Patel1,2, M Kate Grabowski1, Charlotte A Gaydos2,3, Thomas C Quinn3,4, Aaron A R Tobian1. 1. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. 3. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 4. Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Baltimore, Maryland, USA.
Abstract
BACKGROUND: Chlamydia trachomatis is the most common nationally notifiable sexually transmitted infection in the United States; however, the seroprevalence of C. trachomatis infection is unknown. METHODS: This cross-sectional study was conducted among 1725 females aged 18 to 39 years who provided serum and urine samples in the 2013 through 2016 National Health and Nutrition Examination Surveys. Presence of anti-C. trachomatis Pgp3 immunoglobulin G (IgG) was determined using both an enzyme-linked immunosorbent assay (ELISA) and multiplex bead array (MBA). Weighted seroprevalence estimates were calculated. Correlates of seroprevalence were examined by multivariable Poisson regression. RESULTS: In 2013 through 2016, overall seroprevalence of C. trachomatis Pgp3 IgG was 30.0% (95% confidence interval [CI], 25.5-35.0) as measured by ELISA and 29.4% (95% CI, 25.8-33.0) as measured by the MBA assay. Overall agreement between tests was 87.1% (1503/1725). There was a high positive agreement by the MBA assay with current detection of chlamydia in urine (86% [36/42]), a past-year diagnosis of chlamydia (81.8% [27/33]), and a history of treatment for pelvic inflammatory disease (60.7% [37/61]). Seroprevalence of C. trachomatis Pgp3 IgG, as measured by MBA, was significantly higher among non-Hispanic Blacks (68.0%; adjusted prevalence ratio (aPR) = 2.7 [95% CI, 2.3-3.3]), Mexican Americans (30.9%; aPR = 1.5 [95% CI, 1.2-1.9]), and other Hispanics (35.0%; aPR = 1.9 [95% CI, 1.4-2.5]) compared with non-Hispanic Whites (21.4%). A higher lifetime number of sexual partners and a younger age at sexual debut was also associated with higher seroprevalence. CONCLUSION: Both the ELISA and MBA serologic assays revealed a high prevalence of antibodies to C. trachomatis Pgp3 in young adult females in the US household population. There were major racial/ethnic disparities in exposure to C. trachomatis, with increased vulnerability among non-Hispanic Black females.
BACKGROUND: Chlamydia trachomatis is the most common nationally notifiable sexually transmitted infection in the United States; however, the seroprevalence of C. trachomatis infection is unknown. METHODS: This cross-sectional study was conducted among 1725 females aged 18 to 39 years who provided serum and urine samples in the 2013 through 2016 National Health and Nutrition Examination Surveys. Presence of anti-C. trachomatis Pgp3 immunoglobulin G (IgG) was determined using both an enzyme-linked immunosorbent assay (ELISA) and multiplex bead array (MBA). Weighted seroprevalence estimates were calculated. Correlates of seroprevalence were examined by multivariable Poisson regression. RESULTS: In 2013 through 2016, overall seroprevalence of C. trachomatis Pgp3 IgG was 30.0% (95% confidence interval [CI], 25.5-35.0) as measured by ELISA and 29.4% (95% CI, 25.8-33.0) as measured by the MBA assay. Overall agreement between tests was 87.1% (1503/1725). There was a high positive agreement by the MBA assay with current detection of chlamydia in urine (86% [36/42]), a past-year diagnosis of chlamydia (81.8% [27/33]), and a history of treatment for pelvic inflammatory disease (60.7% [37/61]). Seroprevalence of C. trachomatis Pgp3 IgG, as measured by MBA, was significantly higher among non-Hispanic Blacks (68.0%; adjusted prevalence ratio (aPR) = 2.7 [95% CI, 2.3-3.3]), Mexican Americans (30.9%; aPR = 1.5 [95% CI, 1.2-1.9]), and other Hispanics (35.0%; aPR = 1.9 [95% CI, 1.4-2.5]) compared with non-Hispanic Whites (21.4%). A higher lifetime number of sexual partners and a younger age at sexual debut was also associated with higher seroprevalence. CONCLUSION: Both the ELISA and MBA serologic assays revealed a high prevalence of antibodies to C. trachomatis Pgp3 in young adult females in the US household population. There were major racial/ethnic disparities in exposure to C. trachomatis, with increased vulnerability among non-Hispanic Black females.
Authors: Patrick J Horner; Gillian S Wills; Rosy Reynolds; Anne M Johnson; David A Muir; Alan Winston; Andrew J Broadbent; David Parker; Myra O McClure Journal: Sex Transm Infect Date: 2013-02-21 Impact factor: 3.519
Authors: William M Geisler; Apurva Uniyal; Jeannette Y Lee; Shelly Y Lensing; Shacondra Johnson; Raymond C W Perry; Carmel M Kadrnka; Peter R Kerndt Journal: N Engl J Med Date: 2015-12-24 Impact factor: 91.245
Authors: Stephanie N Taylor; Barbara Van Der Pol; Rebecca Lillis; Edward W Hook; William Lebar; Thomas Davis; Deanna Fuller; Leandro Mena; Paul Fine; Charlotte A Gaydos; David H Martin Journal: Sex Transm Dis Date: 2011-07 Impact factor: 2.830
Authors: Gillian S Wills; Patrick J Horner; Rosy Reynolds; Anne M Johnson; David A Muir; David W Brown; Alan Winston; Andrew J Broadbent; David Parker; Myra O McClure Journal: Clin Vaccine Immunol Date: 2009-04-08
Authors: Diana L Martin; Ryan Wiegand; Brook Goodhew; Patrick Lammie; Carolyn M Black; Sheila West; Charlotte A Gaydos; Laura Dize; Harran Mkocha; Mabula Kasubi; Manoj Gambhir Journal: Sci Rep Date: 2015-12-21 Impact factor: 4.379
Authors: Paula B Blomquist; Stephanie J Mighelsen; Gillian Wills; Eleanor McClure; Anthony E Ades; Daphne Kounali; J Kevin Dunbar; Myra O McClure; Kate Soldan; Sarah C Woodhall; Patrick Horner Journal: PLoS One Date: 2018-12-17 Impact factor: 3.240
Authors: Sarah Gwyn; Gretchen Cooley; Brook Goodhew; Stephan Kohlhoff; Natalie Banniettis; Ryan Wiegand; Diana L Martin Journal: Am J Trop Med Hyg Date: 2017-09-21 Impact factor: 2.345
Authors: Gloria E Anyalechi; Jaeyoung Hong; Damien C Danavall; Diana L Martin; Sarah E Gwyn; Patrick J Horner; Brian H Raphael; Robert D Kirkcaldy; Ellen N Kersh; Kyle T Bernstein Journal: Clin Infect Dis Date: 2021-10-20 Impact factor: 20.999